Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights
Nuvectis Pharma(US:NVCT) Globenewswireยท2025-08-05 11:30NXP900 becomes the lead drug candidate after successfully completing the Phase 1a dose escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers; initiation of Phase 1b program is imminentStrengthened cash position following a July At-The-Market (ATM) shares acquisition by a healthcare-dedicated institutional investor; June 30, 2025 proforma cash position of approximately $39 million FORT LEE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. ...